Knowing the Flip Side of the Coin: Ibrutinib Associated Cystoid Macular Edema
- 4 Downloads
A 62-year-old man, normotensive, non-diabetic, was diagnosed with CLL in October 2009, Rai stage 3, Binet stage B. He was treated initially with chlorambucil monotherapy for 12 months due to symptomatic massive splenomegaly and achieved a partial response. In 2012, he received 6 cycles of Bendamustine–Rituximab (BR) chemoimmunotherapy and achieved a partial response. After 18 months, he presented with a second relapse. Molecular studies (FISH–CLL panel) revealed both 11q and 13q deletion. Patient was initiated on Ibrutinib (Imbruvica) monotherapy. Initially, he tolerated ibrutinib well and achieved a partial response. Due to recurrent sino-nasal infections and low IgG levels (IgG, 203 mg/dl), he received intravenous immunoglobulin 0.4 g/kg monthly for 6 months. After 4 years on ibrutinib, (September 2018), he reported visual blurring, with intermittent flashes of light in both eyes for the previous 1 year. Due to these symptoms, he underwent a left eye cataract surgery;...
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Saenz-de-Viteri M, Cudrnak M (2019) Bilateral cystoid macular edema in a patient with chronic lymphocytic leukemia treated withibrutinib. LeukLymphoma 60(3):842–844Google Scholar
- 6.Shaikh H, Khattab A, Faisal MS, Chilkulwar A, Albrethsen M, Sadashiv S, Fazal S (2018) Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—a single institution experience and a review of literature. J Oncol Pharm Pract 25:1078155218788707Google Scholar
© Indian Society of Hematology and Blood Transfusion 2019